肺癌术前新辅助化疗是否增加肺部感染的对比研究

Comparative study on preoperative neoadjuvant chemotherapy for lung cancer

目的研究肺癌患者术前新辅助化疗对肺部感染的影响。方法选择医院接受外科手术治疗的肺癌患者84例,根据是否接受术前新辅助化疗分为两组:48例接受术前新辅助化疗联合手术治疗(观察组),36例直接行手术治疗(对照组),对比两组术后1个月客观疗效、术后生存率(1年、3年、5年)及术后1个月肺部感染等发生情况。结果观察组近期总有效率为79.17%,高于对照组的52.78%(P<0.05);观察组术后1个月的肺部感染率为14.58%,与对照组的11.11%(4/36)比较无统计学差异(P>0.05);观察组术后1年生存率为89.58%,与对照组的80.56%比较无统计学差异(P>0.05);观察组术后3、5年生存率分别为83.33%(40/48)、60.42%(29/48),均较对照组的61.11%(22/48)、33.33%(12/36)明显提高(P<0.05)。结论肺癌患者术前实施新辅助化疗能够改善临床预后,提高远期生存率,且不增加术后肺部感染发生风险,可安全应用。

Objective To study the effects of preoperative neoadjuvant chemotherapy on lung infection in patients with lung cancer. Methods A total of 84 patients with lung cancer received surgical treatment in our hospital were divided into two group according to whether they received preoperative neoadjuvant chemotherapy, i.e., an observation group （n=48） and a control grou （n= 36）. The observation group received preoperative neoadjuvant chemotherapy while the control group received surgical treatment directly. The curative effects one month after the operation, the postoperative survival rates （one year, three years and five years）, and the rates of pulmonary infection one month after the operation between the two groups were compared. Results The total effective rate in in the observation group was 79.17%, which was 52.78% higher than that in the control group（P〈 0.05）; the rate of pulmonary infection in the observation group one month after the operation was 14.58% , with no significant difference from that in the control group （11.11%, 4/36）（P〉 0.05）; the postoperative survival rate in the observation group one year after the operation was 89.58%, with no significant difference from that in the control group （80.56%） （P 〉 0.05）; the survival rates in the observation group three and five years after the operation were 83.33%（40/48） and 60.42% （29/48）, respectively, significantly higher than those in the control group （61.11% ,22/48） and 33.33% （12/36）） （P 〈 0.05）. Conclusion Preoperative neoadjuvant chemotherapy can improve the clinical prognosis of the patients with lung cancer, improve the long-term survival rate of the patients, and increase no risk of postoperative pulmonary infection, so it may be applied safely.